Author

Kerry L. Burnstein

University of MiamiORCID 0000-0002-7351-0963Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:proteomics· 1

Frequent Co-Authors

Beronica A. OcasioiD· 1 shared C Blanco· 1 shared Jiaming HuiD· 1 shared M. J. Martinez· 1 shared Maria J. Martinez· 1 shared MV Revuelta· 1 shared Nahuel PeinettiiD· 1 shared RLZ Lyles· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioinformatics

Beronica A. OcasioORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintNov 9, 2025

BUB1B MITOTIC KINASE DRIVES THERAPY RESISTANT PROSTATE CANCER

M. J. Martinez, C Blanco, Nahuel Peinetti…·Kerry L. Burnstein

This study identifies BUB1B as a driver of castration-resistant prostate cancer and shows its role in enzalutamide resistance, suggesting it as a therapeutic target.

DOI 10.1101/2025.11.09.687448

humanproteomics

𝕏 PostBluesky

BioinformaticsbioRxivPreprintNov 15, 2024

Pan-Cancer Drug Sensitivity Prediction from Gene Expression using Deep Learning

Beronica A. Ocasio, Jiaming Hu, Vasileios Stathias…·Stephan C. Schürer

This paper develops a deep learning model to predict drug sensitivity in cancer using gene expression data and perturbation signatures, validated in prostate cancer cell lines.

DOI 10.1101/2024.11.15.623715

humanbulk RNA-seq

𝕏 PostBluesky